AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05701800 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Sterile liquid for injection
Study NCT05597514 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3D printed educational model
Description: Slide-based presention plus 3D printed airway suction model
Study NCT05597514 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tranditional model education
Description: Slide-based presention plus tranditional model
Study NCT05242146 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GB5121
Description: Capsule containing GB5121
Study NCT06538714 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MIIT
Description: 12-week supervised exercise program consisting of moderate-intensity interval training (MIIT)~MIIT: 3 series of 4-8 repetitions of 30-s of work at 70-75% of MAS and 30-s of active recovery at 50% of MAS.~3 exercise sessions per week.~Additionally, participants receive no individualized nutritional counseling.
Study NCT06538714 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MIIT + HIIT
Description: 12-week supervised exercise program consisting of moderate-intensity interval training (MIIT) (6-week) and high-intensity interval training (HIIT) (6-week).~MIIT: 3 series of 4-8 repetitions of 30-s of work at 70-75% of MAS and 30-s of active recovery at 50% of MAS.~HIIT: 3 series of 5 repetitions of 30-s of work at 100% of MAS and 30-s of active recovery at 50% of MAS for weeks 7-9, as well as two series of 10 repetitions of 30-s of work at 100% of MAS and 30-s of active recovery at 50% of MAS for weeks 10-12.~3 exercise sessions per week. Additionally, participants receive no individualized nutritional counseling.
Study NCT06538714 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control group
Description: Habitual physical activity No additional physical intervention~Additionally, participants receive no individualized nutritional counseling.
Study NCT06539689 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sperstent® peripheral spot stent system
Description: Sperstent® peripheral spot stent system, Percutaneous Transluminal Angioplasty (PTA), Digital Subtraction Angiography（DSA）
Study NCT06539689 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Everflex® self-expanding peripheral stent system
Description: Everflex® self-expanding peripheral stent system, Percutaneous Transluminal Angioplasty (PTA), Digital Subtraction Angiography（DSA）
Study NCT05701800 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Shingrix
Description: Sterile suspension for injection
Study NCT05315388 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Immersion therapy in nature - Vitamin N
Description: Usual therapy group The first saliva sample will be taken upon awakening to determine cortisol concentration. At their workplace, they will be asked to remain seated and silent for 3 minutes, the following will be taken: blood pressure, heart rate, psychological instruments (stress-anxiety), blood sample.~Group 2A and Group 2B In the natural environment, a saliva sample will be taken upon awakening to determine cortisol concentration. After arrival at the site, they will be asked to remain seated and silent for 3 minutes, the following will be taken: blood pressure, heart rate, psychological instruments (stress-anxiety), blood sample.~The first phase is a session of observation of the site for 15 minutes. A slow, unhurried walk will be performed for 1 hour and 45 minutes. The order of activities (sitting and walking) will be established to ensure reliability of physiological measurements.
Study NCT05154903 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Citicoline 500 MG
Description: Citicoline will be administered in continuous iv infusion in a dose of 2000 mg per day for the first week following AIS then by oral route for the next 5 weeks.
Study NCT06240897 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CURATE.Dtx
Description: CURATE.Dtx is a self-guided digital multitasking game that involves a combination of four subtasks played simultaneously, targeting different cognitive domains.
Study NCT06240897 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optional games
Description: The patient will first be asked how he/she feels and what they have done that day. The patient then selects a digital local pet (dog, cat, bird) and can customize its appearance, name and background location. The player can interact with their pet via several actions such as feed, bathe, train and accessorize. Playing with digital pets can help reduce stress and anxiety in the elderly. It can be a positive distraction in alleviating the elderly's worries and discomforts. In order to purchase accessories for their digital pet, they are encouraged to play short games that include Grocery Snap, Down Memory Lane and Pet Escape. These games are aimed at improving memory and reduce cognitive decline.
Study NCT06119737 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Effects of exercises on TSH levels
Study NCT06119737 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Effects of exercises on TSH levels
Study NCT06542809 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: Recruitment will take place through routine paediatric endocrinology consultations with physicians registered with BELSPEED. These doctors will take the time to explain the questionnaire. And allow the patient to complete it.
Study NCT06346561 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: the reduction of controlled hypotension and the control of hemodynamic responses of the body
Study NCT06346561 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Labetalol
Description: the reduction of controlled hypotension and the control of hemodynamic responses of the body
Study NCT06224829 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pain Inducing Massage
Description: 60 seconds of direct pressure to the neck resulting in 5/10 pain . This will be repeated four times for a total of 240 seconds
Study NCT06224829 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pain Free Massage
Description: 60 seconds of direct pressure to the neck resulting in 0/10 pain . This will be repeated four times for a total of 240 seconds
Study NCT06224829 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cold Water Bath
Description: Participants will place their hand in a cold water bath maintained at 6 to 8 degrees Celsius for 60 seconds. This will be repeated four times for a total of 240 seconds.
Study NCT06222255 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transanal Irrigation (TAI)
Description: The combination of transanal irrigation (TAI) and Loperamide (Lopmin®) involves administering Loperamide orally, with a daily dosage of 2 mg for males (2 tablets once daily) and 1 tablet for females (1 tablet once daily). This is complemented by the use of TAI, a method in which patients self-administer water into the rectum through an enema, aiming to enhance bowel management and potentially alleviate symptoms associated with LARS (Low Anterior Resection Syndrome).
Study NCT05081739 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Prospera Transplant Assessment
Description: Prospera™ detects allograft rejection noninvasively and with high accuracy by measuring the fraction of dd-cfDNA in the patient's blood, without the need for prior donor or recipient genotyping.~Prospera is a commercially available LDT developed by Natera, Inc. Natera is a laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA).
Study NCT05081739 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endomyocardial biopsy
Description: Subjects will undergo surveillance EMB per the institution's standard clinical care, which is expected to be approximately every other week in months 2 and 3, then monthly through month 6, then every 1-3 months through the end of month 12.
Study NCT05263869 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRG002
Description: Administrated intravenously
Study NCT06620016 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Circulating microRNAs.
Description: Pre and post-surgery evaluation of peripheral blood circulating microRNAs levels.
Study NCT05814510 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Asthma CHAMPS full program
Description: Full program includes (1) education for staff, students, and caregivers (2) environmental education and intervention (3) asthma care coordination (4) resources
Study NCT05814510 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Asthma CHAMPS Wait List Control
Description: Stepped wedge design
Study NCT06008925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell))
Description: Intratumoral injection only. Dosing days may be Day 1 or Days 1-3 only.
Study NCT06008925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab Injection
Description: Administered once at 3 mg/kg intravenously on Days 8 and 22 of each cycle.
Study NCT04947033 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TJ210001 Injection
Description: The test drug TJ210001 will be preset with 5 escalation dose levels: 0.3mg/kg, 1mg/kg, 3mg/kg, 10mg/kg and 15mg/kg, administered once a week.
Study NCT05108181 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Muscle typology + exercise training
Description: Exercise training: Participants perform 9 weeks of strength training at 60% of their 1RM.
Study NCT05108181 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Muscle typology + training frequency
Description: Training frequency: leg A and arm A of the participants train 3 times per week, leg B and arm B train 2 times per week.
Study NCT04530682 — intervention group
Intervention type: BIOLOGICAL
Intervention: Biological samples
Description: Serum and plasma samples. At baseline, 6, 12 and 24 months
Study NCT04760470 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Technology-assisted upper extremity rehabilitation
Description: Subjects get 6 weeks of technology-assisted upper extremity rehabilitation
Study NCT05548244 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Activation Therapy
Description: Participants will be seen for a maximum of 16 sessions of therapy focused on increasing rewarding behaviors (16 individual therapy sessions of 1-hour, 2 of which include the BSIS component) over 16 weeks. BA intervention includes monthly booster sessions offered throughout 6-month follow up. If needed, two extra sessions will be allowed during treatment.
Study NCT05548244 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Baseline assessment procedures
Description: Completion of the K-SADS and CDRS-R to assess MDD, and the Wechsler Abbreviated Scale of Intelligence - 2nd Edition to assess IQ.
Study NCT05146128 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strengthening exercises
Description: The participants had to perform specific exercices 3 times a week during 8 weeks
Study NCT05606068 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Paxman Limb Cryocompression System (PLCS)
Description: The study population will comprise of cancer patients scheduled to receive weekly paclitaxel chemotherapy for a maximum of 12 cycles.~Cryocompression will be applied during every cycle of chemotherapy for a duration of up to 4 hours. All chemotherapy patients will receive 30 minutes pre-infusion cooling and 30 minutes post-infusion cooling. Cryocompression for each cycle will not exceed 4 hours. Chemotherapy and concomitant limb cryocompression are performed for 12 cycles and may be continued further in consultation with the PI. Overall, limb cryocompression will be administered for no longer than four hours.
Study NCT05039905 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 99mTc-MSA-ICG
Description: Intratumoral injection of 99mTechnetium-manosylated albumin-indocyanine green to lung cancer patients
Study NCT04862091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone Acetate Tablets (I)
Description: Abiraterone Acetate Tablets (I)
Study NCT04862091 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ZYTIGA®
Description: ZYTIGA®
Study NCT06573580 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The essential public health service（EPHS）for COPD
Description: Each group plans to recruit 3,000 participants. For the intervention group, the community-based management includes adding COPD management-related content to the primary public health service. This includes: Providing at least four follow-ups during the project at the 3rd, 6th, 9th, and 12th months. During each follow-up, patients must complete the COPD Patient Follow-up Questionnaire and receive oral health education and targeted clinical advice from the general practitioner (GP). In addition, the GPs must also distribute educational booklets and materials, record symptom assessment results and acute exacerbation situations, and provide targeted clinical advice and clinical decisions to the COPD patients according to the checklist of Chinese guideline for management of COPD in primary care. At the baseline and the last follow-up, patients need to undergo a routine physical examination, pulmonary function test, and bronchodilator test at their community health centers
Study NCT05063149 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Broncho-Vaxom
Description: Broncho-Vaxom is a bacterial extract comprising lyophilised fractions of 21 different inactivated bacterial strains, which are frequently causing RTI.
Study NCT05063149 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo powder from a capsule will be given, which will be indistinguishable from the active study drug.
Study NCT06694974 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: APP calculation for FIB-4
Description: the investigators plan to use the smartphone App for FIB-4 calculation and notify the patients.
Study NCT06694974 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Standard Care (in control arm)
Description: The standard group proceeds as regular practice
Study NCT05729022 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound microendoscopic technique
Description: Ultrasound-guided microendoscopic lumbar transforaminal epidural steroid injection
Study NCT05729022 — intervention group
Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Fluoroscopy
Description: Fluoroscopy-guided lumbar transforaminal epidural steroid injection.
Study NCT05301933 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Parent Training (BPT)
Description: BPT is an evidence-based psychosocial intervention that is directed exclusively to parent of children with ADHD and related disorders. BPT focuses on instructing parents to use approaches to enhance the parent-child relationship (e.g., quality time, praise) and proactive discipline strategies (e.g., time out, reward systems) to reduce challenging child behavior.
Study NCT06569043 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breakfast Bar
Description: Packaged breakfast bar product available in retail stores
Study NCT05381792 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Bacterial gene markers test
Description: Bacterial gene markers test using qPCR
Study NCT06572969 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Elastic-Resistance Kick Training
Description: Athletes used tailored Elastic Resistance training
Study NCT06572969 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No Elastic-Resistance Kick Training
Description: Regular Taekwondo regimen without Elastic Resistance training
Study NCT06573866 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Participatory workplace intervention
Description: The Participatory Workplace Intervention (PWI) is a process intervention in which a trained process facilitator guides an employee and their manager in identifying work-related obstacles and finding solutions to overcome or manage these obstacles. Its primary goal is to achieve consensus between employee and manager with respect to the most obstructive obstacles for functioning at work and feasible solutions. Following consensus, the stakeholders formulate and agree upon a plan of action and execute the plan. Subsequently, the implementation (process) of the plan of action will be evaluated. Six months after the evaluation, a follow-up will take place to determine whether new obstacles have emerged and whether a new cycle of process steps should be initiated.
Study NCT06309199 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Biogaia
Description: Biogaia is a probiotics product that contain Limosilactobacillus reuteri DSM 17938, sunflower oil and MCT oil
Study NCT06309199 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Limosilactobacillus reuteri DSM 17938, sunflower oil and MCT oil
Study NCT06573593 — intervention group
Intervention type: DRUG
Intervention: Tofacitinib
Description: In the real-world settings, patients with AA treated with tofacitinib.
Study NCT06573593 — intervention group
Intervention type: DRUG
Intervention: Baricitinib
Description: In the real-world settings, patients with AA treated with Baricitinib.
Study NCT06573593 — intervention group
Intervention type: DRUG
Intervention: Ruxolitinib
Description: In the real-world settings, patients with AA treated with Ruxolitinib.
Study NCT06573593 — intervention group
Intervention type: DRUG
Intervention: Upadacitinib
Description: In the real-world settings, patients with AA treated with Upadacitinib.
Study NCT06573593 — intervention group
Intervention type: DRUG
Intervention: Abrocitinib
Description: In the real-world settings, patients with AA treated with Abrocitinib.
Study NCT06573593 — intervention group
Intervention type: DRUG
Intervention: Ritlecitinib
Description: In the real-world settings, patients with AA treated with Ritlecitinib.
Study NCT05635747 — intervention group
Intervention type: DEVICE
Intervention: Relizorb Enzyme Cartridge
Description: Tube feeds run across device to digest fats.
Study NCT06024954 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: aromatherapy
Description: Patients in the aromatherapy group use 5% lavender oil with a diffuser for 15-20 minutes in accordance with the Aromatherapy-Clinical Guideline For Midwives. NHS.~Trust 1-15) has been applied. The diffuser was placed 30 cm from the participants and five (5) drops of essential lavender oil were placed on the filter paper. Within 10-15 minutes after the completion of the inhalation, data collection forms were applied again, and pain, anxiety, blood pressure, pulse and respiratory rate were evaluated.
Study NCT06024954 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: music therapy
Description: The relaxing music group listened to specially composed MusiCure® compositions in soft rhythm, including melodies with harp, cello, strings and sound elements from nature (eg rain, bird, forest sound). Listened with headphones for 20 minutes.
Study NCT06024954 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: aromatherapy and music therapy
Description: Inpatients will be given music with a loudspeaker with the effect of aromatherapy inhaler for three consecutive days. Within 10-15 minutes after the completion of the inhalation, data collection forms will be applied again, pain, anxiety, blood pressure, pulse, respiratory rate were evaluated.
Study NCT04902105 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: ecopipam HCL
Description: oral tablets
Study NCT04902105 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Mefenamic acid
Description: oral capsules
Study NCT04902105 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Divalproex Sodium ER
Description: oral tablets
Study NCT06701903 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITI-1284 10 mg
Description: ITI-1284 10 mg tablet, taken once daily, sublingual administration.
Study NCT06701903 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITI-1284 20 mg
Description: ITI-1284 20 mg tablet, taken once daily, sublingual administration.
Study NCT06701903 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablet, taken once daily, sublingual administration
Study NCT05278156 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPL500036 - low dose
Description: CPL500036 is to be oral administered. Each patient is to take 2 capsules with active substance and 2 capsules of placebo daily.
Study NCT05278156 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPL500036 - high dose
Description: CPL500036 is to be oral administered. Each patient is to take 4 capsules with active substance daily.
Study NCT05278156 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is to be oral administered. Each patient is to take 4 capsules of placebo daily.
Study NCT04874922 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gestational Diabetes Training Intervention based on Planned Behavior Theory
Description: On the basis of Planned Behavior Theory, an training intervention is planned in three stages for medical nutrition, physical activity and gestational diabetes follow-up.
Study NCT04874922 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Gestational Diabetes Training Intervention based on standart
Description: Standard training for gestational diabetes will be given once at 28 weeks of gestation.
Study NCT06702098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iNK cells
Description: Induced pluripotent stem cells derived NK cells.